NRIFF Stock UPDATES Nuvo Research Inc (NRIFF) 2.4400 08/03/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nuvo Research Inc (NRIFF) 2.4400 $NRIFF

Chrysler Group Reports Full-Year 2013 Net Income of $2.8 Billion, Including a $962 Million Non-Cash Tax Benefit
PR Newswire - Wed Jan 29, 4:26AM CST
-- Chrysler Group LLC's full-year net income was $2.8 billion, including a $962 million non-cash tax benefit related to the release of valuation allowances on deferred tax assets; full-year 2012 net income was $1.7 billion

Nuvo Research announces notice of Intention to Grant a European Patent for PENNSAID® 2%
PR Newswire - Thu May 09, 6:30AM CDT
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that the European Patent Office has issued a notice of Intention to Grant a European Patent that provides protection for the Company's PENNSAID® 2% product. Upon grant by the European Patent Office, the patent can be officially validated in over 37 European countries.

Nuvo Research to Complete Share Consolidation
PR Newswire - Tue May 07, 6:30AM CDT
Nuvo Research Inc. (TSX: NRI) (the "Company" or "Nuvo" , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced that it will proceed with its proposed share consolidation (the "Consolidation" , as approved by the shareholders of Nuvo at the annual and special meeting held on May 15, 2012, on the basis of 65 pre-Consolidation common shares for one (1) post-Consolidation common share.

Nuvo Research announces 2013 First Quarter Results
PR Newswire - Wed May 01, 4:00PM CDT
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the first quarter ended March 31, 2013.

Nuvo Research Announces European Launch of Pliaglis(R) by Galderma
Business Wire - Tue Apr 23, 6:45AM CDT
Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A. (Galderma), today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology. Marketing licenses have been issued in 14 of the 16 European countries which are listed in the European Marketing Application for Pliaglis.

Nuvo Research announces European launch of Pliaglis® by Galderma
PR Newswire - Tue Apr 23, 6:30AM CDT
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A. (Galderma), today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology. Marketing licenses have been issued in 14 of the 16 European countries which are listed in the European Marketing Application for Pliaglis.

Acute Pain - Pipeline Review, H1 2013
M2 - Fri Apr 05, 7:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gdw5kx/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H1 2013" report to their offering. 'Acute Pain - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Pain. Acute Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Acute Pain. - Identi

Nuvo Research announces 2012 Fourth Quarter & Year-End Results
PR Newswire - Wed Mar 27, 4:00PM CDT
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the fourth quarter and year ended December 31, 2012.

Nuvo Research provides additional information regarding Pennsaid 2%
CNW Group - Mon Mar 18, 6:30AM CDT
Nuvo Research Inc. (Nuvo) (TSX:NRI) announced today that a Question and Answer document has been posted on its website to provide additional information to Nuvo shareholders regarding the regulatory status of Pennsaid 2% in the United States. Follow this link to access the document - Pennsaid 2% Q&A.

Nuvo Research announces U.S. launch of Pliaglis® by Galderma
CNW Group - Mon Mar 11, 6:30AM CDT
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Laboratories, L.P., the U.S. affiliate of Galderma Pharma, S.A. (Galderma), today announced the U.S. launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology.

Nuvo Research announces FDA response to PENNSAID® 2% NDA
PR Newswire - Tue Mar 05, 6:00AM CST
Nuvo Research Inc. (Nuvo) (TSX:NRI) announced today that its U.S. licensing partner, Mallinckrodt, the Pharmaceuticals Business of Covidien (NYSE:COV), has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following the review of Mallinckrodt's New Drug Application (NDA) for diclofenac sodium topical solution, 2% w/w (PENNSAID 2%).

Nuvo Research announces settlement agreement with Apotex in PENNSAID® generic litigation
CNW Group - Tue Jan 29, 6:30AM CST
Nuvo Research Inc. (Nuvo) (TSX: NRI) announced today that it has entered into a settlement agreement with Apotex Inc. and Apotex Corp. (together Apotex) respecting patent infringement litigation brought by Nuvo and Nuvo's U.S. licensing partner, Mallinckrodt Inc. (Mallinckrodt), in response to Apotex's filing of an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of PENNSAID (diclofenac sodium topical solution) 1.5% w/w (PENNSAID).



Scroll down for more posts ▼

Top 10 Most Recent News Articles

AMP Tests Debt Market With €1.25 Billion Green Notes

Updated Category News Views 101

Refinancing season has arrived early at Ardagh Metal Packaging, and it is carrying a hefty €1.25 billion price tag. AMP has launched senior secured floating-rate green notes, with proceeds intended to retire two batches of secured debt due in 2028 and leave additional cash on the balance sheet for general corporate purposes, including capital expenditure. This is not...

Continue Reading
Hanon's BMW Thermal Win Matters Beyond the Trophy Case Today

Updated Category News Views 96

A 16-Kilogram Box Just Grabbed the Auto Supply Chain’s Attention Hanon Systems did not win these two 2026 PACE honors by polishing up some old hose-and-valve package. Its Highly Integrated Cooling Entity, or HICE, is aimed right at a stubborn electric-vehicle problem: keeping a vehicle’s thermal systems controlled without turning the architecture into a sprawling,...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 183

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 54

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 49

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 85

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Stitch AI Targets Banking’s Hardest Automation Gap

Updated Category News Views 25

The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 217

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 131

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading

Top 5 Most Recently Viewed Articles

BrainsWay Achieves Record Revenue and Strategic Growth in 2025

Updated Category News Views 256

Exploring BrainsWay's Remarkable Q2 Results BrainsWay Ltd. (NASDAQ: BWAY), a prominent player in neurostimulation treatments for mental health disorders, recently announced its extraordinary financial performance for the second quarter of 2025. The company achieved a record quarterly revenue of $12.6 million, marking a notable 26% increase compared to the same quarter in...

Continue Reading
CDC Foundation Pushes for Urgent Ebola Response

Updated Category News Views 33

Sounding the Alarm on Ebola In a world where crises come and go like the seasons, the latest Ebola outbreak in the Democratic Republic of the Congo (DRC) and Uganda ought to command our undivided attention. We've seen this movie before, yet here we are with an Ebola variant—Bundibugyo this time—that threatens to spiral out of control. The CDC Foundation has sounded...

Continue Reading
Apple Faces Class Action Over Alleged AI Misrepresentation

Updated Category News Views 279

Apple's Legal Challenges: Class Action Lawsuit Over AI Features Pomerantz LLP has announced the initiation of a class action lawsuit against Apple Inc. (NASDAQ: AAPL) and select executives, focusing on claims surrounding the company’s advertised artificial intelligence capabilities. This legal action stems from allegations of misleading information disseminated to...

Continue Reading
Celebrate Togetherness with Aperol's Inaugural Aperolidays

Updated Category News Views 240

Introducing Aperolidays: A Celebration of Togetherness Aperol, the beloved Italian aperitivo, is stepping into the holiday spirit by announcing the inaugural Aperolidays. This unique celebration aims to infuse joy and connection into the winter season, inviting everyone to gather and enjoy the quintessential Italian way of life. New Festive Merchandise and Experiences...

Continue Reading
Acorai Unveils Breakthroughs in Heart Failure Monitoring Solutions

Updated Category News Views 233

Acorai's Impactful Results in Heart Failure Management Acorai, a clinical-stage company focused on innovative ways to manage heart failure, recently shared impressive findings from the extensive 1,600-patient CAPTURE-HF study. The study focused on a novel, non-invasive multi-sensor device aimed at improving the way healthcare professionals monitor heart failure patients....

Continue Reading